Skip to content

People

Paul Biondi

Executive Partner

Paul joined Flagship Pioneering in 2019 as Executive Partner, Flagship Pioneering and President, Pioneering Medicines. In his role at Flagship, Paul works with growth company CEOs and their teams to achieve the best attainable value for each company and serves on the boards of selected Flagship companies including Seres Therapeutics (NASDAQ: MCRB) and Valo Health. As a member of Flagship’s senior leadership team, Paul is involved in strategic and operational aspects of Flagship, including leading Pioneering Medicines.

Pioneering Medicines is an initiative of Flagship dedicated to conceiving and developing an innovative pipeline of life-changing treatments for patients. By harnessing the power of Flagship’s scientific platforms, Pioneering Medicines will create novel medicines that deliver benefits to more patients, sooner. Pioneering Medicines also enters into strategic partnerships to jointly conceive new products by combining partners' R&D priorities with Flagship's unique platform capabilities, providing partners access to the full spectrum of innovation across Flagship as well as the R&D expertise that Pioneering Medicines offers.

Paul joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (BMS). Most recently, Paul served as the Senior Vice President of Strategy and Business Development where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy, and for pursuing strategic transactions to access external innovation, enhance BMS’s capabilities and strengthen the company’s portfolio. Prior to this role, Paul held a series of leadership roles within BMS’ R&D organization overseeing strategy, portfolio and project management, and clinical and business operations.

Prior to BMS, Paul spent nine years at Mercer Management Consulting. He received his M.B.A. from the J.L. Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.